Evdoxia Kyriazopoulou
Overview
Explore the profile of Evdoxia Kyriazopoulou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kyriazopoulou E, Akinosoglou K, Florou E, Kouriannidi E, Bogosian A, Tsachouridou O, et al.
Int J Antimicrob Agents
. 2024 Dec;
65(1):107405.
PMID: 39647797
Background: Anakinra was approved by the European Medicines Agency and received Emergency Use Authorization by the United States Food and Drug Administration for patients with COVID-19 pneumonia at risk for...
2.
Kranidioti E, Ricano-Ponce I, Antonakos N, Kyriazopoulou E, Kotsaki A, Tsangaris I, et al.
Crit Care Med
. 2024 Oct;
52(11):e536-e544.
PMID: 39418210
Objective: To investigate the metabolomic profiles associated with different immune activation states in sepsis patients. Design: Subgroup analysis of the PROVIDE (a Personalized Randomized trial of Validation and restoration of...
3.
Marantos T, Kyriazopoulou E, Angelakis E, Kitsos D, Chondrogianni M, Mpizta G, et al.
Vaccine
. 2024 May;
42(22):126001.
PMID: 38796324
Background: Immunogenicity of influenza and pneumococcal vaccines varies and requires further elucidation in patients with multiple sclerosis (MS) under treatment with disease-modifying therapies (DMTs). Methods: Adult MS patients who consented...
4.
Kyriazopoulou E, Dalekos G, Metallidis S, Poulakou G, Papanikolaou I, Tzavara V, et al.
Shock
. 2024 Mar;
61(3):395-399.
PMID: 38517242
We aimed to evaluate heparin-binding protein (HBP) as a marker of prognosis of unfavorable outcome in COVID-19 pneumonia. This was a post hoc analysis of the SAVE clinical trial investigating...
5.
Kyriazopoulou E, Hasin-Brumshtein Y, Midic U, Poulakou G, Milionis H, Metallidis S, et al.
Crit Care
. 2024 Mar;
28(1):73.
PMID: 38475786
Background: Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions associated with response to anakinra (human interleukin 1...
6.
Giamarellos-Bourboulis E, Aschenbrenner A, Bauer M, Bock C, Calandra T, Gat-Viks I, et al.
Nat Immunol
. 2024 Jan;
25(1):19-28.
PMID: 38168953
Sepsis remains a major cause of morbidity and mortality in both low- and high-income countries. Antibiotic therapy and supportive care have significantly improved survival following sepsis in the twentieth century,...
7.
Marantos T, Kyriazopoulou E, Lekakis V, Voumvourakis K, Tsiodras S
J Neurol Sci
. 2023 Dec;
456:122852.
PMID: 38142541
Background: Seroconversion rate of vaccines varies and requires further elucidation in patients with multiple sclerosis (MS) under treatment with disease-modifying therapies (DMTs). We aimed to investigate this in a systematic...
8.
Kyriazopoulou E, Giamarellos-Bourboulis E, Akinosoglou K
Expert Rev Mol Diagn
. 2023 Sep;
23(11):945-958.
PMID: 37691280
Introduction: This review summarizes current progress in the development of biomarkers to guide immunotherapy in oncology, rheumatology, and critical illness. Areas Covered: An extensive literature search was performed about biomarkers...
9.
Kyriazopoulou E, Leventogiannis K, Tavoulareas G, Mainas E, Toutouzas K, Mathas C, et al.
Sci Rep
. 2023 Mar;
13(1):3814.
PMID: 36882572
We aimed to develop presepsin as a marker of diagnosis of severe infections of either bacterial and viral origin. The derivation cohort was recruited from 173 hospitalized patients with acute...
10.
Tsangaris I, Antonakos N, Fantoni M, Kaplanski G, Kyriazopoulou E, Veas F, et al.
Shock
. 2023 Mar;
59(3S Suppl 1):16-20.
PMID: 36867757
Optimal management of septic patients requires accurate assessment of both current severity status and prognosis. Since the 1990s, substantial advances have been made in the use of circulating biomarkers for...